SecBot SecBot

ASMB

ASSEMBLY BIOSCIENCES, INC.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001426800 Biotech & Drug Discovery
$20.30 +0.63 (+3.20%)
Oct 27 4:00 PM ET · prev $19.67
Market cap
$404.0M
Small cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$52.00
+156% · range $43.00–62.00
Next earnings
Nov 9
in 12 days · EPS est. −$0.49
1 year
−34.3%
from $30.89 · Oct 28
30 days
−14.0%
from $23.61
52-week range
$19.67–38.50
−47% from high · low Oct 26
Avg volume 20D
232.3K
shares / day
Short interest
2.91M
≈14.3% of shares · +3.2%
Days to cover
11.1
at average volume
Insider net
−$14.7K
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BULLISH 2 reports · 90 days
Balance 0 bearish · 1 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/2 ·Next Earnings date, Nov 9, 2026
Strongest BULLISH Assembly Biosciences reported Q2 2026 EPS of -$0.20, beating consensus of -$0.53 by 62.3%, and collaboration…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $14.7K.

  • InstitutionsBULLISH

    Q2 2026: 20 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    10 of 11 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.505 → −$0.495 over 90 days. 2 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +3.2% to 2.91M shares. 11.1 days to cover, ≈14.3% of shares.

  • TrendDOWNTREND

    25% below its 50-day average. New closing low $19.67 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
FARALLON CAPITAL MANAGEMENT, L.L.C.ADD1,604,590$44.1M
BlackRock, Inc.DOUBLED766,819$21.1M
Point72 Asset Management, L.P.ADD460,593$12.7M
MILLENNIUM MANAGEMENT LLCADD298,807$8.2M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED280,424$7.7M
Schonfeld Strategic Advisors LLCDOUBLED242,153$6.7M
STATE STREET CORPDOUBLED171,931$4.7M
GOLDMAN SACHS GROUP INCDOUBLED137,833$3.8M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts
Buy 91% rate it Buy or better
Strong Buy4Buy6Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +156%.Targets as of Oct 28, 2026.

Recent actions
DateFirmActionRating
Sep 1, 2026Mizuho
MAINTAIN
MAINTAINOutperform
Sep 1, 2026UBS
INITIATE
INITIATEBuy
Aug 18, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Jun 15, 2026Mizuho
MAINTAIN
MAINTAINOutperform
May 28, 2026Guggenheim
REITERATE
REITERATEBuy
May 4, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$14.7K
sold · 2 insiders
DateInsiderTypeValue
Jun 17, 2026
Bjorkquist Jeanette M
PFO and PAO
SELL$674.25
Jun 4, 2026
McHutchison John G
Director
AWARD8,000 sh
Jun 4, 2026
Mahony Susan
Director
AWARD8,000 sh
Jun 4, 2026
Johnson-Pratt Lisa
Director
AWARD8,000 sh
Jun 4, 2026
Houghton Michael
Director
AWARD8,000 sh
Jun 4, 2026
Consylman Gina
Director
AWARD8,000 sh
Jun 4, 2026
ALTIG ANTHONY E
Director
AWARD8,000 sh
May 26, 2026
GILEAD SCIENCES, INC.
10%+ Owner
AWARD$12.5M

Earnings setup

Estimates
Nov 9
reports in 12 days
−$0.49
EPS estimate, this quarter
+2%
estimate change, 90 days
2↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.49-$1.12–-$0.16+0.0%$7.3M
Next Q$0.85-$1.17–$3.19+0.0%$34.5M
Current FY-$0.12-$2.86–$2.28+0.0%$63.4M
Next FY-$2.57-$4.83–$0.05+0.0%$34.1M

Short side

FINRA· Oct 15, 2026
2,913,451
shares short
+3.2%
vs prior settlement
11.1
days to cover
≈14.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Oct 5, 2026 Other
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodyn
Aug 15, 2026 SEC
Assembly Biosciences (ASMB) saw a strong institutional accumulation cluster in Q2 2026, with 6 buyers adding $25.8M in…
INST-CLUSTER · Impact 4/10
Aug 13, 2026 SEC
Assembly Biosciences reported Q2 2026 EPS of -$0.20, beating consensus of -$0.53 by 62.3%, and collaboration revenue…
PRESS-RELEASE · Impact 6/10
Jun 30, 2026 Inst.
FARALLON CAPITAL MANAGEMENT, L.L.C. · ADD
1,604,590 shares ($44.1M)
Jun 30, 2026 Inst.
BlackRock, Inc. · DOUBLED
766,819 shares ($21.1M)
Jun 17, 2026 Insider
Bjorkquist Jeanette M sold 29 shares
PFO and PAO @ $23.25 ($674.25)
Jun 11, 2026 SEC
Five mega-passive institutional investors (Vanguard, BlackRock, State Street, Morgan Stanley, BofA) all increased…
INST-CLUSTER · Impact 3/10
Jun 4, 2026 Insider
McHutchison John G was granted 8,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 9, 2026
Earnings date
ASMB Q3 2026 Earnings Scheduled · 2026-11-09
Recent
Oct 5, 2026
Press release
Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of…
Sep 30, 2026
Short interest
Short Interest: ASMB up 35% to 2.8M shares
Settlement 2026-09-30 | Days to cover: 6.83 | ≈13.86% of shares outstanding (est.)
Sep 8, 2026
Contract
Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
Aug 13, 2026
Earnings
Assembly Biosciences Reports Second Quarter 2026 Financial Results and Recent Updates
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing…
Aug 4, 2026
Earnings date
ASMB Q2 2026 Earnings Scheduled — 2026-08-04

SecBot reports

8 filings · 2 press releases · 2 bullish · 1 bearish · 5 neutral
All ASMB filing & press-release reports (10)